H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $457 and keeps a Buy rating on the shares after the company announced the acquisition of Alpine Immune Sciences (ALPN). The ability to target both BAFF and APRIL now allows Vertex to go behind a host of immunoinflammatory diseases apart from IgA nephropathy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal
- RBC says pain opinion leader ‘notably negative’ on Vertex’s VX-548
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex announces acceptance of NDS for exagamglogene autotemcel
- Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
